Drug Information

Drug General Information
Drug ID
D0F5BL
Former ID
DIB015756
Drug Name
EXO-230
Synonyms
GLY-230
Indication Diabetic neuropathy [ICD9: 250, 250.6, 356.0, 356.8; ICD10:E11.40] Phase 1/2 [522142]
Company
Glycadia Inc
Canonical SMILES
N(c1c(CC(=O)O)cccc1)c1cc(Cl)ccc1
Target and Pathway
Target(s) Prostaglandin G/H synthase 1 Target Info Agonist [544348]
BioCyc Pathway C20 prostanoid biosynthesis
KEGG Pathway Arachidonic acid metabolism
Metabolic pathways
Platelet activation
Serotonergic synapse
NetPath Pathway TGF_beta_Receptor Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
PathWhiz Pathway Arachidonic Acid Metabolism
WikiPathways Prostaglandin Synthesis and Regulation
Arachidonic acid metabolism
Phase 1 - Functionalization of compounds
Eicosanoid Synthesis
Selenium Micronutrient Network
References
Ref 522142ClinicalTrials.gov (NCT00544934) Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects. U.S. National Institutes of Health.
Ref 544348Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats. Physiol Rep. 2013 September; 1(4): e00083.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.